Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.
IGM Biosciences, Inc. (IGMS) is a clinical-stage biotechnology company pioneering IgM antibody therapeutics for cancer, autoimmune disorders, and inflammatory diseases. This page serves as the definitive source for official news, press releases, and financial updates directly from the company and verified partners.
Investors and stakeholders will find timely updates on clinical trial milestones, regulatory developments, and strategic collaborations with global pharmaceutical leaders. The curated content includes earnings reports, research breakthroughs, and pipeline advancements related to the company’s proprietary IgM platform, which enables multispecific antibody engineering.
Bookmark this page to track IGM Biosciences’ progress in developing novel therapies that leverage the unique binding capabilities of IgM antibodies. Visit regularly for unfiltered access to critical updates that may impact long-term investment strategies and sector analysis.
IGM Biosciences reported a net loss of $58.6 million, or $1.33 per share, for Q2 2022, compared to a $38.7 million loss in Q2 2021. The company received a $150 million upfront payment from Sanofi as part of a collaboration agreement to develop IgM antibodies. Cash and investments totaled $513.2 million at the end of Q2 2022. The firm continues advancing its clinical trials for imvotamab and IGM-8444, with initial safety updates expected soon. IGM anticipates filing IND applications for two new therapies this year and has projected 2022 cash reserves to be around $400 million.
IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on June 8, 2022, at 3:00 p.m. EST in New York. The event will be available via live webcast, with a replay accessible for 90 days on the company’s website. IGM specializes in developing IgM antibodies, leveraging a proprietary technology platform to address manufacturing challenges and enhance therapeutic applications compared to IgG antibodies.
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will partake in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 9:30 a.m. EST in New York. The event will be live-streamed on the Company’s website, with a replay available for 90 days. IGM Biosciences specializes in developing engineered IgM antibodies and has established a proprietary technology platform to enhance therapeutic use, overcoming previous manufacturing challenges since its inception in 2010.
IGM Biosciences has announced significant developments including a $150 million upfront payment from Sanofi as part of their exclusive global collaboration for researching IgM antibodies. The company also raised $230 million through a public equity offering. Clinical progress continues with IGM-2323 and IGM-8444, and the filing of IND applications for IGM-7354 and IGM-2644 is expected this year. Financials reveal a net loss of $51.9 million for Q1 2022, with operating expenses projected between $250 million and $260 million for the year.
IGM Biosciences Secures $150 Million from Sanofi
IGM Biosciences, Inc. (Nasdaq: IGMS) has successfully completed its collaboration agreement with Sanofi, with the $150 million upfront payment marking the commencement of the partnership. This collaboration focuses on developing IgM antibody agonists for three oncology and three immunology targets. The deal also includes potential milestone payments exceeding $6 billion, profit-sharing agreements, and royalties on global sales. CEO Fred Schwarzer expressed enthusiasm about the collaboration, emphasizing its potential to advance IGM's innovative IgM antibody platform.
IGM Biosciences (NASDAQ: IGMS) announced the closure of its public offering of 8,695,653 shares of non-voting common stock and an additional 1,304,347 shares of voting common stock after underwriters exercised their option. The offering price was $23.00 per share, generating approximately $230 million in gross proceeds before expenses. J.P. Morgan, BofA Securities, Stifel, and Guggenheim acted as joint book-running managers. This offering was registered under a Form S-3 with the SEC, providing investors with detailed information through the final prospectus supplement.
IGM Biosciences, Inc. (NASDAQ: IGMS) has priced its underwritten public offering of 8,695,653 shares of non-voting common stock at $23.00 per share, aiming to raise approximately $200 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 1,304,347 shares of voting common stock. The offering is set to close on or around April 1, 2022, pending customary conditions. J.P. Morgan, BofA Securities, Stifel, and Guggenheim Securities are the joint book-running managers for this offering.
IGM Biosciences, Inc. (NASDAQ: IGMS) announced a proposed public offering of $200 million in common stock, with an option for underwriters to purchase an additional $30 million. The offering is subject to market conditions and will be conducted through a registration statement with the SEC. J.P. Morgan, BofA Securities, Stifel, and Guggenheim Securities are joint book-running managers for the offering. The company specializes in engineered IgM antibodies, aiming to overcome manufacturing challenges in the field.
IGM Biosciences announced a global collaboration with Sanofi targeting oncology, autoimmune, and inflammation areas. IGM will receive a $150 million upfront payment, with potential total milestones exceeding $6 billion. The partnership will leverage IGM's IgM antibody technology. The initiation of two Phase 2 studies for IGM-2323 in patients with DLBCL and FL was also announced. For 2021, IGM reported a net loss of $165.2 million, or $4.93 per share, while cash and investments were at $229.5 million. A conference call is scheduled for 8:00 a.m. ET today.
IGM Biosciences, a clinical-stage biotechnology company, announced a conference call on March 29, 2022, at 8:00 am ET to discuss a global collaboration with Sanofi. Interested parties can join by calling (866) 649-1996 domestically or (409) 217-8769 internationally, using conference ID 4983742. A live audio webcast will be available on their website under the Investors section, and a replay will be accessible for 90 days post-event. The company specializes in engineered IgM antibodies, aiming to overcome existing manufacturing challenges.